136
A.A. Jensen et al. / European Journal of Pharmacology 497 (2004) 125–137
Eisele´, J.-L., Bertrand, S., Galzi, J.-L., Devillers-Thie´ry, A., Changeux,
J.-P., Bertrand, D., 1993. Chimaeric nicotinic–serotonergic receptor
combines distinct ligand binding and channel specificities. Nature 366,
479–483.
data is gratefully acknowledged, and Drs. Preben Hansen
(University of Copenhagen) and G. Cornali (Leo Pharma-
ceuticals) are acknowledged for their help with the elemental
analyses. Drs. James W. Patrick and David J. Julius are
thanked for their kind gifts of nicotinic receptor and 5-HT3
receptor cDNAs. Drs. Ken Kellar, Yingxian Xiao and Joe
Henry Steinbach are thanked for generously providing us
with the a3h4 and a4h2 cell lines. This work was supported
by the Lundbeck Foundation, the Danish Technical Research
Council, the Danish Medical Research Council, the Augus-
tinus Foundation, and the Director Ib Henriksen Foundation.
Enraf-Nonius, 1989. CAD-4 Software, Version 5.0. Enraf-Nonius, Delft,
The Netherlands.
Fitch, R.W., Xiao, Y., Kellar, K.J., Daly, J.W., 2003. Membrane potential
fluorescence: a rapid and highly sensitive assay for nicotinic receptor
channel function. Proc. Natl. Acad. Sci. U. S. A. 100, 4909–4914.
Gotti, C., Fornasari, D., Clementi, F., 1997. Human neuronal nicotinic
receptors. Prog. Brain Res. 53, 199–237.
Hine, J., Cholod, M.S., King, R.A., 1974. Bifunctional catalysis of the
deuteration of acetone-d6 by 3-dimethylaminopropylamine, 2-(dime-
thylaminomethyl)cyclopentylamines, and polyethylenimines. J. Am.
Chem. Soc. 96, 835–845.
Holladay, M.W., Dart, M.J., Lynch, J.K., 1997. Neuronal nicotinic
acetylcholine receptors as targets for drug discovery. J. Med. Chem.
40, 4169–4194.
References
Abood, L.G., Grassi, S., 1986. [3H]Methylcarbamylcholine, a new radio-
ligand for studying brain nicotinic receptors. Biochem. Pharmacol. 35,
4199–4202.
Jaroszewski, J.W., Matzen, L., Frølund, B., Krogsgaard-Larsen, P., 1996.
Neuroactive polyamine wasp toxins: nuclear magnetic resonance
spectroscopic analysis of the protolytic properties of philanthotoxin-
343. J. Med. Chem. 39, 515–521.
Anderson, D.J., Arneric, S.P., 1994. Nicotinic receptor binding of
[3H]cytisine, [3H]nicotine and [3H]methylcarbamylcholine in rat brain.
Eur. J. Pharmacol. 253, 261–267.
Jensen, A.A., Mikkelsen, I., Frølund, B., Br7uner-Osborne, H., Falch, E.,
Krogsgaard-Larsen, P., 2003. Carbamoylcholine homologs: novel and
potent agonists at neuronal nicotinic acetylcholine receptors. Mol.
Pharmacol. 64, 865–875.
Arneric, S.P., Brioni, J.D., 1999. Neuronal Nicotinic Receptors: Pharma-
cology and Therapeutic Opportunities. Wiley-Liss, New York, NY.
Baker, E.R., Zwart, R., Sher, E., Millar, N.S., 2004. Pharmacological
properties of the a9a10 nicotinic acetylcholine receptors revealed by
heterologous expression of subunit chimeras. Mol. Pharmacol. 65,
453–460.
Johnson, C.K., 1976. ORTEP II Report ORNL-5138. A Fortran Thermal-
Ellipsoid Plot Programme for Crystal Structure Illustrations. Oak-Ridge
National Laboratory, Tennessee, USA.
Karlin, A., 2002. Emerging structure of the nicotinic acetylcholine
receptors. Nat. Rev., Neurosci. 3, 102–114.
Beene, D.L., Brandt, G.S., Zhong, W., Zacharias, N., Lester, H.A.,
Dougherty, D.A., 2002. Cation–k interactions in ligand recognition
by serotonergic (5-HT3A) and nicotinic acetylcholine receptors: the
anomalous binding properties of nicotine. Biochemistry 41,
10262–10269.
Kinas, R., Pankiewicz, K., Stec, W.J., Farmer, P.B., Foster, A.B., Jarman,
M., 1977. Synthesis and absolute configuration of the optically active
forms of 2-[bis(2-chloroethyl)amino]-4-methyltetrahydro-2H-1,3,2-
oxazaphosphorine 2-oxide (4-methylcyclophosphamide). J. Org. Chem.
42, 1650–1652.
Bissell, E.R., Finger, M., 1959. Fluorine-containing nitrogen compounds: I.
Trifluoroethylamines. J. Org. Chem. 24, 1256–1259.
Levin, E.D., 2002. Nicotinic receptors in the nervous system. In: Simon,
S.A., Nicolelis, M.A.L. (Eds.), Methods and New Frontiers in Neuro-
science. CRC Press, Boca Raton.
Blessing, R.H., 1987. Data reduction and error analysis for accurate single-
crystal diffraction intensities. Crystallogr. Rev. 1, 3–58.
Blessing, R.H., 1989. DREADD—data reduction and error analysis for
single-crystal diffractometer data. J. Appl. Crystallogr. 22, 396–397.
Brejc, K., van Dijk, W.J., Klaassen, R.V., Schuurmans, M., van Der Oost,
J., Smit, A.B., Sixma, T.K., 2001. Crystal structure of an ACh-binding
protein reveals the ligand-binding domain of nicotinic receptors. Nature
411, 269–276.
Lindstrom, J., 1997. Nicotinic acetylcholine receptors in health and disease.
Mol. Neurobiol. 152, 193–222.
Nonius, 1999. COLLECT. Nonius, Delft, The Netherlands.
Parker, M.J., Beck, A., Luetje, C.W., 1998. Neuronal nicotinic receptor h2
and h4 subunits confer large differences in agonist binding affinity.
Mol. Pharmacol. 54, 1132–1139.
Corringer, P.-J., Le Nove`re, N., Changeux, J.-P., 2000. Nicotinic receptors
at the amino acid level. Annu. Rev. Pharmacol. Toxicol. 40, 431–458.
Davies, A.R.L., Hardick, D.J., Blagbrough, I.S., Potter, B.V.L., Wolsten-
holme, A.J., Wonnacott, S., 1999. Characterisation of the binding of
[3H]methyllycaconitine: a new radioligand for labelling a7-type
neuronal nicotinic acetylcholine receptors. Neuropharmacology 38,
679–690.
Paterson, D., Nordberg, A., 2000. Neuronal nicotinic receptors in the
human brain. Prog. Neurobiol. 61, 75–111.
Perrin, C.L., Fabian, M.A., 1996. Multicomponent NMR titration for simul-
taneous measurement of relative pKas. Anal. Chem. 68, 2127–2134.
Punzi, J.S., Banerjee, S., Abood, L.G., 1991. Structure–activity relation-
ships for various N-alkylcarbamyl esters of choline with selective
nicotinic cholinergic properties. Biochem. Pharmacol. 41, 465–467.
Ransom, R.W., Stec, N.L., 1988. Cooperative modulation of [3H]MK-801
binding to the N-methyl-d-aspartate receptor-ion channel complex by
l-glutamate, glycine, and polyamines. J. Neurochem. 51, 830–836.
Romanelli, M.N., Gualtieri, F., 2003. Cholinergic nicotinic receptors:
competitive ligands, allosteric modulators, and their potential applica-
tions. Med. Res. Rev. 23, 393–426.
DeTitta, G.T., 1985. ABSORB: an absorption correction programme for
crystals enclosed in capillaries with trapped mother liquor. J. Appl.
Crystallogr. 18, 75–79.
Dfrje, F., Wess, J., Lambrecht, G., Tacke, R., Mutschler, E., Brann, M.R.,
1991. Antagonist binding profiles of five cloned human muscarinic
receptor subtypes. J. Pharmacol. Exp. Ther. 256, 727–733.
Duisenberg, A.J.M., 1992. Indexing in single-crystal diffractometry with an
obstinate list of reflections. J. Appl. Crystallogr. 25, 92–96.
Duisenberg, A.J.M., 1998. EvalCCD. PhD thesis, University of Utrecht,
The Netherlands.
Sabey, K., Paradiso, K., Zhang, J., Steinbach, J.H., 1999. Ligand binding
and activation of rat nicotinic a4h2 receptors stably expressed in
HEK293 cells. Mol. Pharmacol. 55, 58–66.
Sharples, C.G., Kaiser, S., Soliakov, L., Marks, M.J., Collins, A.C.,
Washburn, M., Wright, E., Spencer, J.A., Gallagher, T., Whiteaker, P.,
Wonnacott, S., 2000. UB-165: a novel nicotinic agonist with subtype
selectivity implicates the alpha4beta2* subtype in the modulation of
dopamine release from rat striatal synaptosomes. J. Neurosci. 20,
2783–2791.
Dwoskin, L.P., Crooks, P.A., 2001. Competitive neuronal nicotinic receptor
antagonists: a new direction for drug discovery. J. Pharmacol. Exp.
Ther. 298, 395–402.
Eglen, R.M., Choppin, A., Watson, N., 2001. Therapeutic opportunities
from muscarinic receptor research. Trends Pharmacol. Sci. 22, 409–414.